Tirzepatide FAQ: common questions answered
A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Also called: Mounjaro, Zepbound, LY3298176, LY-3298176, Tirz.
GLP-1 / GIP / glucagon agonists · Dual GIP and GLP-1 receptor agonist · Evidence: Approved drug.
- Is Tirzepatide FDA-approved? Yes: Mounjaro (type 2 diabetes: adults and ages 10+. Adult major cardiovascular risk reduction in high-risk type 2 diabetes.); Zepbound (adult chronic weight management; moderate-to-severe sleep apnea in adults with obesity.). 503A shortage discretion ended 2025-03-05; 503B ended 2025-03-19. FDA proposed 503B exclusion 2026-04-30; no PCAC inclusion decision verified.
- How do people take it? Under the skin, once weekly. Source: drug label.
- What's the difference between Tirzepatide and Semaglutide? Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Semaglutide: a GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter. Why people pair them: people add it for extra appetite suppression after a plateau; no tirzepatide–semaglutide combination trial was found.
- Can I take it with Semaglutide? People add it for extra appetite suppression after a plateau; no tirzepatide–semaglutide combination trial was found. The Zepbound label advises against another GLP-1 drug; severe constipation is reported. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Not banned. It is on the watch list (WADA 2026). Markers of tirzepatide are monitored in and out of competition. It is not prohibited on that basis.
- How long does a mixed vial last? Label single-dose: ≤30°C for up to 21 total days. Multi-dose/KwikPen: discard by 30 days after first use, 30 room-temp days, or 4 weekly doses.
Related to Tirzepatide
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
- Exenatide: An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA · 2026
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society., Mozaffarian D et al. · American journal of lifestyle medicine · 2025
- Update on the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) pharmacy compounding changes, Therapeutic Goods Administration · 2024
- Assessment report: Mounjaro, European Medicines Agency
- DailyMed - MOUNJARO- tirzepatide injection, solution MOUNJARO KWIKPEN- tirzepatide injection, solution, DailyMed
- DailyMed - ZEPBOUND- tirzepatide injection, solution ZEPBOUND KWIKPEN- tirzepatide injection, solution, DailyMed
- GLP-1 medicines for weight loss and diabetes: what you need to know, MHRA · MHRA
- Mounjaro, European Medicines Agency
- MOUNJARO (Eli Lilly Australia Pty Ltd), Therapeutic Goods Administration
- Prescribing, reviewing and stopping tirzepatide, NICE
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.